Risk assessments play a critical role across pharmaceutical environments, influencing how organisations identify vulnerabilities, implement appropriate controls and maintain inspection readiness. Whether assessing manufacturing processes, clinical activities, pharmacovigilance systems or computerised systems, the quality of a risk assessment can have a significant impact on both compliance and operational oversight.
Drawing on practical experience across GMP, GCP, GVP and GLP settings, below are 25 lessons learned from conducting robust risk assessments within regulated pharmaceutical environments.
Governance & Framework
1. Risk management must be proceduralised, not ad hoc.
Embed a formal Quality Risk Management (QRM) SOP aligned with ICH Q9 principles (risk identification, analysis, evaluation, control, review).
2. Define risk acceptance criteria upfront.
Establish quantitative or semi-quantitative thresholds (e.g., RPN limits, criticality tiers) before scoring begins to avoid retrospective bias.
3. Ensure clear risk ownership.
Every risk must have an accountable function (QA, PV, Clinical Ops, Manufacturing, IT), not just a process label.
4. Differentiate compliance risk from patient safety risk.
Regulatory exposure and patient harm are not synonymous; assess both dimensions explicitly.
5. Integrate enterprise risk and GxP risk views.
Avoid siloed assessments – link quality, data integrity, cybersecurity, and supply chain risks.
Methodology & Execution
6. Use the right tool for the right risk.
FMEA is not universally appropriate. Consider HACCP for contamination, fault-tree analysis for system failures, and bow-tie models for high-impact hazards.
7. Score severity first, independently of detectability.
Patient safety and data integrity impact should anchor the model.
8. Avoid inflated detectability assumptions.
“Procedure exists” ≠ effective detection. Challenge control effectiveness with evidence.
9. Validate assumptions with data.
Deviation trends, audit findings, CAPA recurrence, and signal detection outputs should inform scoring.
10. Separate inherent vs. residual risk.
Document pre-control exposure and post-mitigation residual risk clearly for transparency.
11. Do not average risk scores across heterogeneous hazards.
Aggregation can mask critical single-point failures.
12. Consider system interfaces explicitly.
Many critical failures occur at vendor handoffs, safety database integrations, or IVRS/IWRS boundaries.
Vendor & Outsourcing Oversight
13. Third-party risks require independent assessment.
Sponsor reliance on vendor self-assessment is insufficient under GCP/GVP expectations.
14. Assess vendor computerised systems beyond validation certificates.
Evaluate governance, change management, audit trails, and access controls.
15. Contractual controls are not operational controls.
Quality Agreements must translate into oversight mechanisms and KPIs.
Data Integrity & Computerised Systems
16. Embed ALCOA++ principles into risk models.
Attributable, Legible, Contemporaneous, Original, Accurate (plus Complete, Consistent, Enduring, Available, Traceable).
17. Cybersecurity is a GxP risk, not just an IT risk.
Ransomware or access compromise directly affects batch release, PV reporting, and subject safety.
18. Periodic review of validated systems is essential.
Static validation assumptions degrade over time. User access review alone is not a periodic review.
Cross-Functional Engagement
19. Risk workshops outperform single-author assessments.
Cross-functional sessions surface latent process vulnerabilities.
20. Encourage psychological safety in risk discussions.
Underreporting of vulnerability due to hierarchy distorts assessment outputs.
21. Involve SMEs early – QA cannot assess technical failure modes alone.
Lifecycle & Continuous Improvement
22. Risk assessments must be living documents.
Update after major deviations, audits, inspection findings, mergers, or regulatory changes.
23. Link risks directly to CAPA effectiveness checks.
A mitigated risk without verification of control effectiveness is theoretical.
24. Monitor leading indicators, not just lagging deviations.
Trending near-misses, minor deviations, and system alerts provides predictive value.
25. Document rationale with inspection readiness in mind.
Regulators expect transparent logic
Ultimately, effective risk assessments are driven not by documentation alone, but by clear thinking, strong governance and practical decision-making. Organisations that embed risk management as an active, continuously improving discipline will be better positioned to maintain compliance, strengthen oversight and respond effectively to evolving GxP challenges.